Biden's former doctor asks to delay testimony to House panel, citing patient privilege concerns
WASHINGTON — Former U.S. President Joe Biden's physician has asked to delay his testimony before the House oversight committee this week, citing the need for an agreement that will respect doctor-patient confidentiality rules as part of the investigation into Biden's health in office.
Dr. Kevin O'Connor, who served as Biden's physician at the White House, requested a delay until the end of July or early August 'to reach an accommodation that will protect the very substantial privilege and confidentiality interests of Dr. O'Connor and former President Biden,' according to a letter from his lawyer sent to Rep. James Comer of Kentucky on Saturday. The Associated Press obtained a copy of the letter.
A spokesperson for Oversight Republicans said the committee will follow the House's deposition guidelines, which allow for witnesses to assert privilege on a question-by-question basis, with the committee chair ruling on each claim. But O'Connor is not allowed, in the committee's view, to delay or decline a congressional subpoena due to concerns over questions about potentially privileged information.
The back-and-forth is part of a broader struggle over the scope of the House Republican inquiry into Biden's age and mental fitness, with serious implications for both politics and policy. Republicans have also claimed that some policies carried out by the White House 'autopen' may be invalid if it is proven that Biden was mentally incapacitated for some part of his term.
Biden has strongly denied claims that he was not in a right state of mind at any point while in office, calling the claims 'ridiculous and false.'
The House Oversight Committee first requested O'Connor testify before the committee last July, but the Biden White House blocked his testimony. Comer renewed his request in May and later subpoenaed the doctor in June.
David Schertler, the attorney for O'Connor, in the letter said the committee is refusing to 'accommodate to any degree Dr. O'Connor's objections' over protecting privilege. He said the committee's decision was 'unprecedented' and 'alarming' and warned that it threatened broader principles around medical privacy.
Scherlter said O'Connor could face 'serious consequences' for violating his obligations as a doctor, including losing his medical license.
In a June subpoena of O'Connor, Comer said that claims of physician-patient privilege under the American Medical Association's code of ethics 'lack merit' because that code is not part of federal law. He said the committee's subpoena meets the AMA's own requirement that physicians must share a patient's medical information if 'legally compelled to disclose the information' or 'ordered to do so by legally constituted authority.'
Comer has promised that the committee will make all its findings public in a report after the inquiry has finished. He has subpoenaed O'Connor and Anthony Bernal, former chief of staff to former first lady Jill Biden. The committee last month heard voluntary testimony from Neera Tanden, former director of Biden's domestic policy counsel.
The committee has also requested the testimony of nearly a dozen former senior Biden aides, including former White House chiefs of staff Ron Klain and Jeff Zients; former senior advisers Mike Donilon and Anita Dunn; former deputy chief of staff Bruce Reed, former counselor to the president Steve Ricchetti, former deputy chief of staff Annie Tomasini and a former assistant to the president, Ashley Williams.
The Trump White House has waived executive privilege, a principle that protects many communications between the president and staff from Congress and the courts, for almost 10 senior former Biden staffers. That move clears the way for those staffers to discuss their conversations with Biden while he was president.
While the privilege can apply to former staffers, the decision of whether to waive it is decided by the sitting administration.
Matt Brown And Michelle L. Price, The Associated Press
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
15 minutes ago
- CTV News
‘It gives us hope': Quebec expands access to life-extending prostate cancer treatment
A life-altering treatment for prostate cancer with fewer side effects is now more accessible in Quebec. A Quebec man who has spent years fighting for access to a promising prostate cancer treatment says he was overcome with emotion when the province finally approved it last week. Jean Krashevski was first diagnosed with aggressive prostate cancer in 2015. After surgery and 33 rounds of radiation, he hoped the disease was behind him. But within a year and a half, it returned — this time spreading to other parts of his body, including his brain. 'I should be dead by now,' he said. 'But we moved quickly, and we fought hard. This new treatment gives us something we haven't had in a long time: hope.' Pluvicto, the drug for this treatment, is a radiopharmaceutical therapy that delivers targeted radiation directly to prostate cancer cells. It's designed for patients with metastatic castration-resistant prostate cancer who have already undergone hormone therapy and chemotherapy. On July 2, the Quebec government added it to the province's list of publicly covered medications. For Krashevski, who launched a petition a year ago demanding the province fund Pluvicto, it was a long-awaited breakthrough. 'I couldn't believe it when we got the news,' he said. 'I was with my family and we all cried because this treatment is a game-changer — not just for me, but for so many men waiting for this.' Dr. Frédéric Arsenault, president of the Association of Nuclear Medicine Specialists of Quebec, calls the decision 'a milestone.' 'There was a clear gap in treatment options for patients with advanced prostate cancer,' he said. 'Pluvicto fills that gap — it not only prolongs life, but it does so with better quality and fewer to no side effects.' The therapy works by binding to a protein found on the surface of prostate cancer cells called PSMA (prostate-specific membrane antigen). A radioactive atom then delivers targeted radiation directly to the tumour. Because it attacks only the cancer cells and not healthy tissue, Dr. Arsenault explained that the treatment avoids some of the harsh side effects of traditional therapies, including erectile dysfunction, severe fatigue, and damage to surrounding organs. In clinical trials, Pluvicto led to a 50 per cent drop in PSA levels, the key blood marker used to monitor prostate cancer, and significantly delayed disease progression. Until now, patients in Quebec had to pay $27,000 per dose out of pocket, with a full course of six doses totalling over $160,000. Dr. Arsenault said some were able to access it under RAMQ's 'exceptional medications' program, but only on a case-by-case basis with added red tape. Years of waiting and fighting Like many medical experts and prostate cancer patients, Krashevski had been following Pluvicto's development closely. His wife Céline, a biologist, has helped him navigate research, protocols, and treatment options since his diagnosis. Together, they advocated for the drug's approval in Quebec, speaking to doctors, politicians, and the media. 'It was an uphill battle,' he said. 'Some officials were sympathetic but told me their hands were tied, others were dismissive.' Krashevski has undergone multiple rounds of hormone therapy and other treatments that have taken a toll on his body and mind. He continues to stay active — practicing martial arts in a more meditative way — but said the effects of cancer are far-reaching. 'Your sex life changes entirely — you also lose your strength and your muscle mass,' he said. 'Psychologically, it's tough too because you're always just gaining time — one more day, one more treatment — waiting and hoping that something new will come.' He has just undergone a new round of imaging tests and is waiting for the green light to begin Pluvicto. 'I'd love to start tomorrow but there's a protocol,' he said. 'Raising awareness remains key' Krashevski said he wants other men to speak up about prostate cancer — and get screened early, especially if there's a family history. 'It's a simple blood test, and, if you catch it early, the treatment is much easier,' he said. 'Once it metastasizes, it's a whole different ballgame.' He also urged patients to be proactive in their own care — to ask questions, seek second opinions, and bring a trusted person to medical appointments to take notes and advocate. 'We have great doctors here in Quebec, but time is of the essence when you're diagnosed,' he said. 'Don't wait.' Another encouraging aspect of Pluvicto is its potential beyond treating prostate cancer. Dr. Arsenault said the drug is being studied for a range of other cancers, including breast, gastric, liver, and pancreatic cancer. That research is already underway, including in Quebec at McGill's Jewish General Hospital. 'We think that in the next 10 years, there could be 10 other types of cancer or other diseases that will benefit from this kind of treatment,' he said. For now, Krashevski is focused on the next steps in his care. And for the first time in a long time, he says, he's optimistic. 'For a while, I had lost hope, but this news gives me the chance to keep fighting,' he said. 'And, after all these years, I'm still hoping for a chance at full remission.'
CTV News
31 minutes ago
- CTV News
FIFA World Cup to delay B.C. criminal trials
Vancouver Watch Vancouver's hosting of the 2026 FIFA World Cup will push back operations at the B.C. Supreme Court.
CTV News
31 minutes ago
- CTV News
Should garburators be banned in Vancouver?
Vancouver will consider a motion restricting in-sink garbage disposals. Here's why one councillor thinks the city should get rid of them entirely.
